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Background: High-grade (WHO grade III and IV) astrocytomas are aggressive malignant brain tumors affecting
humans with a high risk of recurrence in both children and adults. To date, limited information is available on the
genetic and molecular alterations important in the onset and progression of pediatric high-grade astrocytomas and,
even less, on the prognostic factors that influence long-term outcome in children with recurrence. A-to-I RNA
editing is an essential post-transcriptional mechanism that can alter the nucleotide sequence of several RNAs and is
mediated by the ADAR enzymes. ADAR2 editing activity is particularly important in mammalian brain and is
impaired in both adult and pediatric high-grade astrocytomas. Moreover, we have recently shown that the
recovered ADAR2 activity in high-grade astrocytomas inhibits in vivo tumor growth. The aim of the present study is
to investigate whether changes may occur in ADAR2-mediated RNA editing profiles of relapsed high-grade
astrocytomas compared to their respective specimens collected at diagnosis, in four pediatric patients.
Methods: Total RNAs extracted from all tumor samples and controls were tested for RNA editing levels (by direct
sequencing on cDNA pools) and for ADAR2 mRNA expression (by qRT-PCR).
Results: A significant loss of ADAR2-editing activity was observed in the newly diagnosed and recurrent
astrocytomas in comparison to normal brain. Surprisingly, we found a substantial rescue of ADAR2 editing activity
in the relapsed tumor of the only patient showing prolonged survival.
Conclusions: High-grade astrocytomas display a generalized loss of ADAR2-mediated RNA editing at both
diagnosis and relapse. However, a peculiar Case, in complete remission of disease, displayed a total rescue of RNA
editing at relapse, intriguingly suggesting ADAR2 activity/expression as a possible marker for long-term survival of
patients with high-grade astrocytomas.
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Astrocytoma grade III (anaplastic astrocytoma, AA) and
astrocytoma grade IV (glioblastoma multiforme, GBM)
are malignant, highly aggressive human brain tumors,
characterized by an intrinsic tendency to recur. The me-
dian overall survival (OS) time after diagnosis is 12–18
months in both children and adults and decreases to a
few months for patients with recurrence [1,2]. Despite
multimodal treatment approaches, including extensive sur-
gical resection and innovative radio- and chemotherapies,* Correspondence: angela.gallo@opbg.net
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reproduction in any medium, provided the orthe outcome for patients with high-grade astrocytomas has
not significantly improved over time. Of note, available
data suggest that very young children (age <3 years) have a
more favorable prognosis than older patients with similar
tumors, even if recurrence is common also in this subset
of patients [3].
Differently from adults in which malignant astrocytomas
are the most frequent primary brain tumors, the pediatric
counterparts account for only 6-12% of all brain neo-
plasms [4,5]. Consequently, to date limited information is
available on the genetic and molecular alterations in
pediatric patients important for the onset and progression
of high-grade astrocytomas and even less is known aboutal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Tomaselli et al. BMC Cancer 2013, 13:255 Page 2 of 8
http://www.biomedcentral.com/1471-2407/13/255the prognostic factors that influence the long-term out-
come in children with recurrence [5-7].
A-to-I RNA editing is an essential post-transcriptional
mechanism that changes Adenosine (A) into Inosine (I)
within RNA molecules due to the action of the ADAR
(adenosine deaminase acting on dsRNA) enzymes. As
Inosine is “read” as Guanosine by the splicing and trans-
lation machineries, the ADAR enzymes can generate a
variety of RNAs and proteins different from those genet-
ically coded. Three ADAR enzymes exist in mammals:
ADAR1 and ADAR2 are ubiquitously expressed and
catalytically active, whilst ADAR3 shows brain-specific
expression and is enzymatically inactive [8,9]. ADARs
can bind RNA targets through their RNA-binding do-
mains (RBDs) and convert A into I thanks to the highly
conserved deaminase domain (DM) [8,9]. RNA editing
levels depend on the different substrates/sites, cell types,
tissues and developmental stage [10,11]. Adar1−/− and
Adar2−/− knockout mice die at embryonic or post-natal
stages, respectively, indicating that these enzymes are es-
sential for survival in mammals [12,13].
Compared to other tissues the mammalian brain car-
ries the highest amount of inosines [14]. Indeed several
edited transcripts have been identified in the central ner-
vous system (CNS), where ADAR2 seems to play a
major role [12]. Some transcripts, coding for proteins im-
portant for a correct brain development and function,
undergo editing events that change amino acid sequence
(recoding editing) in crucial positions for protein activity,
such as the receptor subunits of the AMPA glutamate-
gated ion channel (GluR-B, -C, -D), the Kainate receptors
(GluR-5, GluR-6), the potassium voltage-gated channel
(Kv1.1), the serotonin receptor (5-HT2CR) and the α3 sub-
unit of the γ-amino butyric acid (GABA) receptor [9].
Interestingly, it has been shown that glutamate receptor
antagonists inhibit in vitro proliferation of several human
tumor cells, including gliomas [15] and that silencing of a
specific AMPA receptor subunit reduces glioma growth
in vivo [16]. Furthermore, it has been demonstrated that
editing events within GluR-B inhibits glioma cell migra-
tion in vivo [17].
In view of these data, it is not surprising that alter-
ations in A-to-I RNA editing in these transcripts have
been observed in several human diseases affecting the
CNS, including brain tumors [9]. In particular, a general-
ized hypoediting in both adult and pediatric high-grade
astrocytomas when compared to normal brain tissues
has been observed [9,18-21]. Moreover, we have recently
demonstrated that the rescue of ADAR2 activity in as-
trocytoma cells prevents tumor growth in vivo, through
the modulation of a specific molecular pathway involved
in the cell cycle G1/S checkpoint [22].
The aim of the present study is to analyse ADAR2-
mediated RNA editing profiles in four pediatric matchedpairs of high-grade astrocytomas collected at the time of
diagnosis and at recurrence, in order to investigate
whether changes occur throughout disease progression.
Methods
Patients and samples collection
Four pediatric patients with high-grade astrocytomas,
similar tumor location and local recurrences were en-
rolled in this study. The patients’ clinical data are sum-
marized in Table 1.
The matched tumor samples were dissected from the
proliferative core of the tumors and split in two halves,
with one half fixed in 10% formalin for immunohistochem-
istry (IHC) analysis and the second half stored at −80°C for
molecular studies. Non-tumoral white matter samples
(a pool of two), isolated from the same brain area of the tu-
mors and obtained from pediatric patients undergoing
focal brain resection for head injury sequelae (e.g. brain
contusion), were used as normal control after being
anonymized.
The study was revised and approved by the Institutional
Review Board (IRB) of the local committee (Bambino
Gesù Children’s Hospital, Rome) on the use of human
samples for experimental studies. Informed consent was
obtained from all the patients’ parents to the use of bio-
logical samples for research purposes.
Editing analysis
For RNA editing analysis, total RNA was isolated from
tumor and control brain tissues with TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. Total RNAs were treated with
DNAse and cDNAs were generated using the ImProm-II
Reverse Transcription System (Promega, Madison, WI,
USA) and random hexamers or transcript-specific oligo-
nucleotides (available on request). Three independent
RT-PCRs (reverse transcriptase-polymerase chain reac-
tions) were performed for each sample. Direct sequen-
cing (ABI 3500 Genetic Analyzer, Applied Biosystems,
Foster City, USA) was performed on cDNA pools and
the editing levels at specific sites were measured as pre-
viously described [20,23]. Briefly, in the sequence chro-
matogram the Adenosine nucleotide that undergoes
editing appears as a double peak: Adenosine for the un-
edited forms and Guanosine for those edited (the height
of the two peaks was used for calculation of editing
percentage) (Additional file 1: Figure S1).
Analysis of mRNA expression levels
Gene-specific exon-exon boundary PCR products
(TaqMan gene expression assays, Applied Biosystems)
were measured by means of a PE Applied Biosystems
PRISM 7700 sequence detection system during 40
cycles. β-actin mRNA was used for normalization and
Table 1 Clinical features of four children with high-grade astrocytoma
Case 1 Case 2 Case 3 Case 4
Sex F M M F
Age at diagnosis ≤ 13 years ≤ 12 years ≤ 8 years ≤ 3 years
Newly diagnosed tumor
Tumor location P left F left FTP right FP left
Resection GTR GTR GTR GTR
Histology GBM GBM AA GBM
Ki-67 (IHC) >10% 50% 7-10% 60%
Pre-radiation CT / / / infant protocol (*)
RT doses 54 Gys plus TMZ 54 Gys plus TMZ 54 Gys plus TMZ 59 Gys (at time of 3 year old)
Post-radiation CT TMZ (6 courses) TMZ (6 courses) TMZ (6 courses) /
Recurrent tumor
DFS (months) 8 14 33 22
Recurrence local local local local
Resection GTR GTR GTR GTR
Histology GBM GBM AA GBM
Ki-67 (IHC) 40% 50% 60% 50%
Adjuvant CT TMZ /PCV (1 course)° TMZ /PCV (4 courses)° TMZ /PCV (6 courses)° TMZ /irinotecan (12 courses)
Outcome dead dead dead alive
LPS score / / / 90
Disease / / / CR; off therapy
OS (months) 10 26 40 57
P Parietal, F Frontal, FTP Fronto-temporo-parietal, FP Fronto-parietal, GTR Gross Total Resection, GBM Glioblastoma, AA Anaplastic Astrocytoma,
IHC immunohistochemistry, RT Radiotherapy, CT Chemotherapy, TMZ Temozolomide, DFS Disease Free Survival, PCV Procarbazine-Lomustine-Vincristine,
LPS score Lansky performance score (from 100 to 0, with 100= healthy status), CR Complete Remission, OS Overall Survival.
°Until progression and death.
*Infant protocol according to the National Therapeutic Indications for infant with GBM: Methotrexate and Vincristine (1 course), Etoposide (1 course),
cyclophosphamide and Vincristine (1 course), thiotepa (2 courses) followed by stem cell auto-grafting.
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the 2-ΔΔCt method. Real-time assays were repeated in
triplicates from two independent RT-PCRs. The primers
were supplied by Applied Biosystems: ADAR2, ID
Hs00953730_m1; β-actin, ID Hs99999903_m1. The ex-
pression level of each recurrence was calculated as
relative-fold increase compared to that of the corre-
sponding newly diagnosed tumor arbitrarily set to 1.
To test Ki-67 expression levels, we performed semi-
quantitative RT-PCRs directly on the total RNA isolated
from tumor and control tissues. β-actin was used to
normalize the RT-PCR reactions. Ki-67 levels were also
evaluated by IHC on the paraffin-embedded tissues by
two independent experienced neuropathologists.
Results
RNA editing in newly diagnosed versus recurrent pediatric
high-grade astrocytomas
It is emerging the idea that differences in molecular
characteristics can be present in newly diagnosed versus
recurrent malignant high-grade astrocytomas [2,24]. We
therefore investigated whether ADAR2-mediated RNAediting, found to be important in astrocytomas, may vary
throughout disease progression in four pediatric patients
with supratentorial recurrent high-grade astrocytomas
(Table 1).
We focused on recoding editing events of transcripts
that translate into brain membrane receptors or ion
channels, such as the receptor subunit of the AMPA
channel (GluR-B), the receptor subunits of the Kainate
channel (GluR-5 and GluR-6) and the potassium channel
(Kv1.1), because these sites are mainly, if not exclusively,
edited by ADAR2 enzyme [12].
We analyzed editing levels of the GluR-B transcript at
the Q/R and the R/G sites, the GluR-6 transcript at three
recoded positions identified as the I/V, Y/C and Q/R
sites, the GluR-5 transcript carrying the Q/R edited site
and the Kv1.1 transcript carrying the I/V edited site.
Editing levels at all these sites were also tested in normal
white matter tissues used as control and dissected from
the same area of the brain where the tumors developed.
RNA editing analysis of tumor samples at diagnosis
showed a significant loss of ADAR2 activity when com-
pared with control tissues at all the sites analyzed
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Additionally, when we compared the editing profiles of
newly diagnosed tumors with the corresponding re-
lapses, we observed a generalized further loss of editing
levels, with some editing sites showing a statistically sig-
nificant decrease in the relapsed tumors compared with
the previous lesions: the GluR-6 Y/C site (p≤0.05) and
the GluR-5 Q/R site (p≤0.05) of Case 1, the GluR-B R/G
site (p≤0.05) of Case 2 and the GluR-B Q/R site (p≤0.01)
of Case 3 (Figure 1 and Table 2).
Unexpectedly, the recurrence of the youngest patient
(Case 4, age at diagnosis ≤ 3 years; Table 1) displayed a
completely different RNA editing profile in comparison
to the tumor at diagnosis, showing significantly higher
editing levels at all the analyzed sites (Figure 1 and
Table 2).In vivo rescue of ADAR2 RNA editing activity
Considering the surprising results observed in the recur-
rence of Case 4, we decided to analyze in this patient
additional recoding editing sites previously found to be
edited, mainly or partially, by ADAR2. We performed
RNA editing analysis of the Gabra-3 I/M site (edited by
both ADAR1 and ADAR2) [25], the BLCAP Y/C, Q/R
sites (edited by both ADAR enzymes) and the K/R site
(edited mainly by ADAR2) [26,27] in the tumor tissues
of Case 4 and controls.
Editing within the Gabra-3 transcript controls traffick-
ing of α3-containing receptors to the cell membrane [28].
Despite the fact that the role of editing events within
BLCAP are still unknown, it has been proposed that this
protein is a novel prognostic biomarker in bladder cancer
and it is associated with cell proliferation [29].
This further analysis confirmed a rescue of RNA
editing levels in the relapse of Case 4 for all the tested
sites, with editing values similar to those found in nor-
mal brain (Figure 2A). Of note, the only site of BLCAP
transcript showing a significant editing rescue was theTable 2 ADAR2 edited sites and their relative percentage of e
ADAR2 edited sites WM Case 1
(% of editing ± s.e.m.) (Ctrls)
N R N
GluR-B Q/R 100 (±0) 90.3 (±5.6) 92.1 (±0.3) 87.6 (±
R/G 53.2 (±4.2) 21.9 (±6.5) 15.4 (±2) 18.1 (±
GluR-6 I/V 58.1 (±0.7) 20.5 (±3.3) 8.3 (±2.5) 17.1 (±
Y/C 73.5 (±6.9) 32.4 (±0.45) 15.7 (±2) 24.6 (±
Q/R 74.6 (±0.9) 8.6 (±8.6) 3.8 (±3.8) 24.5 (±
GluR-5 Q/R 63.8 (±1) 28.7 (±0.2) 22 (±0.9) 27.6 (±
Kv1.1 I/V 9.6 (±2) 0 (±0) 0 (±0) 0 (±0
WM white matter, N newly diagnosed tumor, R recurrent tumor.
% of editing is expressed as mean of three independent experiments ± S.E.M.K/R site, which is the only one mainly modified by
ADAR2 [26].
In order to rule out any possible unintentional con-
tamination of non-tumor tissue in the relapse of Case 4,
we measured the levels of Ki-67 cell proliferation index
directly on the RNA samples used for the RNA editing
molecular assays (Figure 2A). As expected for neoplastic
tissues, both the newly diagnosed and recurrent tumor
samples of Case 4 showed over-expression of Ki-67 mRNA
when compared with normal white matter (Figure 2B-C).
A similar result on the same samples was obtained by IHC
analysis (Table 1). High Ki-67 levels were also detected by
semi-quantitative RT-PCR (data not shown) and IHC
(Table 1) in the tumor tissues of Cases 1-2-3.
ADAR2 expression levels in pediatric high-grade
astrocytomas
ADAR2 is the enzyme mainly responsible for the recoding
editing at the sites analyzed in this study [12,20]. There-
fore, we investigated whether fluctuation in ADAR2
mRNA occurred in tumor samples that may partially ex-
plain the editing profiles of the all Cases reported.
We found a significant decrease of ADAR2 expression
in the recurrences of Cases 1–3 when compared to their
newly diagnosed tumors (Figure 3). On the contrary, a
significant higher ADAR2 expression level was found in
the relapse of Case 4 when compared with the tumor at
diagnosis (Figure 3), which can correlate with the res-
cued editing profiles found in the recurrence of this
patient (Figure 2A).
Discussion
High-grade astrocytomas are very aggressive brain tu-
mors, with GBM (or astrocytoma grade IV) being one of
the most lethal tumors in humans. Despite the novel
and aggressive surgical/therapeutic approaches, after a
short period of remission these tumors frequently recur,
with a median survival, after recurrence, of only few
months [2]. The molecular mechanisms involved in thediting
Case 2 Case 3 Case 4
R N R N R
1.8) 83.5 (±0.9) 98.15 (±1.1) 83 (±0.7) 98.7 (±1.3) 100 (±0)
3.2) 5 (±2.7) 4.4 (±1.4) 7.9 (±1.9) 15.1 (±1.8) 49.3 (±1.8)
4.8) 12 (±1.5) 0 (±0) 2.7 (±2.7) 12.9 (±1.7) 55.2 (±2.4)
5.1) 15.7 (±1.8) 6.1 (±0.8) 1.9 (±1.9) 12.7 (±0.3) 82.8 (±3.5)
0.1) 19 (±2.7) 3.4 (±3.4) 6.4 (±0.5) 10.3 (±5.3) 75.9 (±0.9)
4.6) 20 (±2.2) 16.4 (±2.4) 21.1 (±1.2) 35.9 (±4.9) 71.5 (±3)
) 0 (±0) 0 (±0) 0 (±0) 0 (±0) 10.7 (±1.7)
Figure 1 RNA editing analysis in Cases 1–4. RNA editing levels at the GluR-B Q/R and R/G sites, GluR-6 I/V, Y/C and Q/R sites, GluR-5 Q/R site
and Kv1.1 I/V site were analyzed in newly diagnosed (dark gray) and recurrent (light gray) high-grade astrocytomas in Cases 1 to 4. The editing
values are expressed as a percentage of the mean of three independent experiments. Error bars indicate standard error of the mean (S.E.M.),
*p<0.05, **p<0.01.
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quent recurrences, as well as the signature associated
with long-term survival and a positive outcome are still
poorly known, especially in children, due to the rarity of
these tumors during the pediatric age [6,24,30].
RNA editing is an essential genetic recoding process
that enhances the molecular diversity of RNAs and pro-
teins at post-transcriptional level to different extents, de-
pending on the cell types and tissues. In particular,
ADAR2-mediated RNA editing is essential for the func-
tional activity of many proteins expressed in the CNS
from fly to mammals [9].
It has been shown that astrocytomas are characterized
by a general decrease of RNA editing mediated by ADAR2
enzyme [19-22,26] and that a correlation exists between
the progressive loss of ADAR2 activity and the increasing
grade of tumor, with the lowest editing levels found in
AAs and GBMs [20]. Furthermore, we have recently dem-
onstrated that a recovery of ADAR2 editing activity in as-
trocytoma cells is necessary and sufficient to significantly
inhibit tumor growth in a mouse model [22].
Considering the above findings, we investigated whether
differences exist in RNA editing profiles mediated by
ADAR2 between malignant high-grade astrocytomas at
initial presentation and their subsequent relapse in the
same patient (Table 1). To the best of our knowledge, thisis the first comparative report of RNA editing analysis
performed on matched pairs of newly diagnosed and re-
current tumor tissues in the same patient.
The small size of patient cohort analyzed in this study is
mainly due to the rarity of high-grade astrocytomas in
children, together to the difficulty in collecting tumor
samples from the same patient both at diagnosis and at
recurrence. Additionally, as RNA editing profiles change
depending on different brain areas [20,31], we needed to
collect tumor samples developed within the same brain re-
gion (supratentorial astrocytomas) from different patients.
We found an overall general decrease in RNA editing
levels in both newly diagnosed and relapsed tumors in 3
out of 4 cases when compared with controls (Figure 1
and Table 2), with a significant further drop of editing in
the recurrences only at few specific editing sites (Figure 1
and Table 2).
These results suggest that ADAR2-mediated RNA
editing, at least on the re-coding editing sites analyzed
herein, is a molecular signature for high-grade astrocyto-
mas that does not dramatically change during tumor re-
currence in children.
The most surprising result was the editing profile of
Case 4, the only surviving patient (Table 1). As com-
pared to diagnosis, its relapse sample showed a recovery
of RNA editing levels at all the sites tested, with values
Figure 2 Comparative molecular analysis in Case 4 versus control. (A) Comparative analysis of the RNA editing levels at the GluR-B Q/R and
R/G sites, GluR-6 I/V, Y/C and Q/R sites, GluR-5 Q/R site, Kv1.1 I/V, Gabra-3 I/M site and BLCAP Y/C, Q/R and K/R sites among normal white matter
(WM, black), newly diagnosed (N, dark gray) and recurrent (R, light gray) tumor tissues of Case 4. The editing values are expressed as a
percentage of the mean of three independent experiments. Error bars indicate standard error of the mean (S.E.M.), *p<0.05, **p<0.01. (B) A
representative example of Ki-67 mRNA expression levels analysed by semi-quantitative RT-PCRs in the control (normal white matter), newly
diagnosed and recurrent tumor samples of Case 4. (C) Densitometric analysis of Ki-67 mRNA expression is represented in arbitrary units calculated
as a relative-fold increase in expression compared to the control arbitrarily set to 1. Each sample was normalized to β-actin mRNA. Error bars
indicate standard error of the mean (S.E.M.) (n=3).
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sected from the same brain area where the tumor devel-
oped (Figure 2A). These findings were unexpected,
considering that previous studies in adult and pediatric
astrocytomas always reported a significant editing de-
crease in high-grade astrocytomas [19-22].Figure 3 ADAR2 expression levels in Cases 1–4. qRT-PCR analysis
of ADAR2 mRNA from newly diagnosed (dark gray) and recurrent
(light gray) tumors in Cases 1 to 4. The expression levels of each
recurrence were calculated as a relative-fold increase compared to
the corresponding newly diagnosed tumor arbitrarily set to 1. Each
sample was normalized to β-actin mRNA. Mean ± s.d. (n=2),
*p<0.05, **p<0.01.Editing activity does not always correlate with mRNA
or protein expression of ADAR enzymes [11]. According
to this, a recent study showed the existence of “media-
tors” (i.e. proteins) that can modulate ADAR2 efficiency
[32]. Nevertheless, we decided to test ADAR2 expression
by qRT-PCR in our patients and only in Case 4 we
found a significant increase of ADAR2 in the relapse
compared to the newly diagnosed tumor (Figure 3). This
finding correlates with the rescued editing profiles ob-
served in the Case 4 relapsed tumor (Figure 2A). Not-
ably, we have recently demonstrated that the forced
expression of the active ADAR2 enzyme in astrocytoma
cells rescues editing levels at specific sites (such as the
ones tested here) and that, most importantly, this editing
rescue is able to inhibit tumor growth with a signifi-
cantly prolonged overall survival of mice injected with
tumor cells overexpressing ADAR2 [22].
At present, little is known regarding the physiological
regulation of ADAR2 expression, however it has been
shown that both its expression and activity are markedly
enhanced in response to glucose in pancreatic islets and
beta-cells [33]. Moreover, it has been shown that in neur-
onal cells the cAMP response binding element (CREB), an
important transcription factor, can induce ADAR2 expres-
sion [34]. The observation that infants follow a different
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suggest that ADAR2 expression and/or RNA editing levels
could be recovered in this particular subset of patients,
possibly due to specific treatments or drugs. Considering
the findings of ADAR2 upregulation in a peculiar Case
(Case 4), we asked whether a possible correlation exist be-
tween ADAR2 mRNA expression and pediatric patient
survival, interrogating available datasets. We found only a
glioma array specific for pediatric patients (but not for in-
fant) in which the clinical outcome was also reported
(http://r2.amc.nl, dataset Paugh-53-MAS5.0-u133p2). We
observed that, at least in this dataset, there is not a statisti-
cally significant correlation between ADAR2 levels and
outcome, even if a slight decrease of ADAR2 expression is
reported for patients died of disease compared to patients
alive (data not shown).
Currently, total tumor resection, aggressive treatment
and diagnosis at a younger age have been associated with
longer survival of pediatric patients with high-grade as-
trocytomas [6,35]. Thus, it is intriguing to speculate that
in very young children high-grade astrocytomas may be
biologically different [3,36]. The hypothesis that younger
patients (as in the Case 4 reported here) might be able
to recover ADAR2 expression/activity, due to still unknown
endogenous cellular factors or maybe induced by specific
treatments or drugs, deserves additional investigations.
Furthermore, it would be worth considering the role
of ADAR2 activity/expression as possible marker for
long-term survival of patients with recurrent high-grade
astrocytomas.Conclusions
Despite the low number of paired samples investigated,
RNA editing mediated by ADAR2 seems to further de-
crease significantly only at few specific sites throughout
disease progression. Moreover, our findings relative to
one peculiar Case (age ≤ 3 years) suggest that ADAR2
activity can be rescued in vivo in tumor cells, raising the
intriguing possibility that editing recovery may have con-
tribute to the favorable outcome of this patient, as sug-
gested by mouse model studies (22).Additional file
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